TickerGuard
Buy Day today: Neutral (56) Mixed market breadth · no major macro event
UNCY

Unicycive Therapeutics Inc

Healthcare · Biotechnology

4.70$ -2.4% vs. previous close Closing price · As of: Sep 25, 2026

Ownership

Ownership Structure

Who owns Unicycive Therapeutics Inc (UNCY)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 99.4% of the shares are freely tradable; institutional investors hold 41.9%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 41.9%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 2.4%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 99.4%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 14.4%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 27Mio.

Largest Shareholders

Institutions

Institutions UNCY
Name Stake (%) Shares Change (%) Date
Octagon Capital Advisors LP 3.59 1,000,000 +0.0 06/30/2026
Nantahala Capital Management, LLC 3.37 939,202 +0.0 03/31/2026
Vanguard Capital Management, LLC 2.91 811,430 +0.0 03/31/2026
Vivo Capital, LLC 1.97 550,000 -69.3 06/30/2026
Logos Global Management LP 1.70 473,563 +0.0 06/30/2026
Diadema Partners LP 1.09 303,676 +186.3 06/30/2026
Millennium Management LLC 0.97 271,456 -80.6 06/30/2026

Funds

Funds UNCY
Name Stake (%) Shares Change (%) Date
Vanguard MStar Total Stk Mkt Idx Invest 2.89 805,716 +0.0 08/31/2026
iShares Russell 2000 ETF 2.18 606,920 -0.6 08/31/2026
Fidelity Small Cap Index 0.96 267,145 +0.0 06/30/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?